{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:11:48Z","timestamp":1794003108424,"version":"4.8.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the prognostic and clinicopathologic value of Ki-67 and profilin 1 immunohistochemical expression in primary pT1 papillary urothelial bladder cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      This study included 88 male and 13 female pT1 primary bladder cancer patients. Demographic characteristics, tumor histological grade, tumor number, presence of concomitant carcinoma\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      , tumor size, and status of recurrence or progression were recorded for each patient. Expression of Ki-67 and profilin 1 was evaluated by immunohistochemical analysis of paraffin-embedded tumor tissues. The Pearson's Chi-square test was used for the analysis of qualitative data, and the Kaplan\u2013Meier method and the log-rank test were used for the survival analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In the mean follow-up period of 52 months, 52 (51.5%) patients experienced recurrence, 24 (23.8%) patients experienced progression, and 17 (16.8%) patients died from bladder cancer-related causes. Ki-67 expression was significantly associated with tumor histological grade (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). In multivariate analysis, Ki-67 positivity had significantly worse outcome for recurrence (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006) and mortality (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.022). Ki-67-positive (Ki-67 index \u226515%) patients had shorter recurrence-free (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003), progression-free (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), and cancer-specific (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003) survival. However, no statistically significant relationship was found between profilin 1 expression and clinicopathologic features and prognosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ki-67 is a highly predictive biomarker for recurrence-free, progression-free, and cancer-specific survival in pT1 bladder cancer patients, in whom prediction of recurrence and progression are difficult. Ki-67 expression can be safely combined with other prognostic factors. However, in pT1 bladder cancer patients, no significant relationship was found between profilin 1 expression and tumor characteristics or prognostic parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_408_19","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T02:33:28Z","timestamp":1604370808000},"page":"434-442","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer"],"prefix":"10.4103","volume":"17","author":[{"given":"Meftun","family":"Culpan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidika Seyma","family":"Ozkanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulay","family":"Zenginkinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Kazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Atis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turhan","family":"Caskurlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20241021","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R2-21-20241021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urolonc.2010.04.003","article-title":"Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium","volume":"28","author":"Goebell","year":"2010","journal-title":"Urol Oncol"},{"key":"R3-21-20241021","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"R4-21-20241021","doi-asserted-by":"crossref","first-page":"e3337","DOI":"10.1097\/MD.0000000000003337","article-title":"High Ki-67 immunohistochemical reactivity correlates with poor prognosis in bladder carcinoma: A comprehensive meta-analysis with 13,053 patients involved","volume":"95","author":"Luo","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"R5-21-20241021","doi-asserted-by":"crossref","first-page":"M111","DOI":"10.1074\/mcp.M111.009449","article-title":"Profilin 1 is a potential biomarker for bladder cancer aggressiveness","volume":"11","author":"Zoidakis","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"R6-21-20241021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder Tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"R7-21-20241021","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"R8-21-20241021","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2012.05.033","article-title":"Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer","volume":"65","author":"Bertz","year":"2014","journal-title":"Eur Urol"},{"key":"R9-21-20241021","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2007.06.030","article-title":"Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: Do risk factors define feasibility of bladder-sparing approach?","volume":"53","author":"Denzinger","year":"2008","journal-title":"Eur Urol"},{"key":"R10-21-20241021","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.urolonc.2013.06.009","article-title":"Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder","volume":"32","author":"Xylinas","year":"2014","journal-title":"Urol Oncol"},{"key":"R11-21-20241021","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0022-5347(17)39613-1","article-title":"Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67","volume":"144","author":"Okamura","year":"1990","journal-title":"J Urol"},{"key":"R12-21-20241021","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s13277-013-1384-9","article-title":"Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"R13-21-20241021","first-page":"1238","article-title":"Correlation of mitotic indices, AgNor count, Ki-67 and Bcl-2 with grade and stage in papillary urothelial bladder cancer","volume":"11","author":"Goyal","year":"2014","journal-title":"Urol J"},{"key":"R14-21-20241021","doi-asserted-by":"crossref","first-page":"42.e13","DOI":"10.1016\/j.urolonc.2013.05.004","article-title":"Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC","volume":"32","author":"Ding","year":"2014","journal-title":"Urol Oncol"},{"key":"R15-21-20241021","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11255-015-1197-4","article-title":"Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy","volume":"48","author":"Wang","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"R16-21-20241021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/15321819.2014.899254","article-title":"Expression of topoisomerase II alpha, Ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma","volume":"35","author":"Ben Abdelkrim","year":"2014","journal-title":"J Immunoassay Immunochem"},{"key":"R17-21-20241021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5114\/pjp.2015.51154","article-title":"Evaluation of different p16 immunostaining methods and the prognostic role of p16\/Ki-67 combined expression in non-muscle invasive bladder cancers","volume":"66","author":"\u00d6zyalva\u00e7li","year":"2015","journal-title":"Pol J Pathol"},{"key":"R18-21-20241021","doi-asserted-by":"crossref","first-page":"e0158891","DOI":"10.1371\/journal.pone.0158891","article-title":"Clinicopathological and prognostic value of Ki-67 expression in bladder cancer: A systematic review and meta-analysis","volume":"11","author":"Tian","year":"2016","journal-title":"PLoS One"},{"key":"R19-21-20241021","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.eururo.2004.12.018","article-title":"P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma","volume":"47","author":"Kr\u00fcger","year":"2005","journal-title":"Eur Urol"},{"key":"R20-21-20241021","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00018-016-2372-1","article-title":"Profilin1 biology and its mutation, actin(g) in disease","volume":"74","author":"Alkam","year":"2017","journal-title":"Cell Mol Life Sci"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_408_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:49Z","timestamp":1787067469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_408_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_408_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}